Latest news
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 14:18:19 GMTSyndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist - SahmSahm · Thu, 06 Aug 2026 07:00:00 GMTSyndax Pharmaceuticals Q2 Earnings Call Highlights - MarketBeatMarketBeat · Wed, 05 Aug 2026 03:50:06 GMTSNDX: Q2 2026 revenue jumped 92% YoY as losses narrowed and pipeline assets advanced - TradingViewTradingView · Tue, 04 Aug 2026 20:10:29 GMTNiktimvo approval in Australia reinforces momentum for macrophage-targeted cGVHD therapies - The Pharma LetterThe Pharma Letter · Wed, 29 Jul 2026 12:43:46 GMT